Javier Pinilla-Ibarz

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: Memorial Sloan Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Javier Pinilla-Ibarz. Retrieved from https://idiyas.com/inventor/javier-pinilla-ibarz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 3

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 88(Granted Patents)

Location History:

New York, NY (US) (2009 - 2014)
Tampa, FL (US) (2016 - 2023)

Company Filing History:

4 out of 621

Memorial Sloan Kettering Cancer Center

patents

3 out of 519

Sloan-Kettering Institute for Cancer Research

patents

Years Active: 2009-2026

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528849 - WT1 HLA CLASS II-BINDING PEPTIDES AND COMPOSITIONS AND METHODS COMPRISING SAME (2026-01-20),

2. 11548924 - WT1 HLA class II-binding peptides and compositions and methods comprising same (2023-01-10),

3. 10221224 - WT1 HLA class II-binding peptides and compositions and methods comprising same (2019-03-05),

4. 9233149 - WT1 HLA class II—binding peptides and compositions and methods comprising same (2016-01-12),

5. 8765687 - WT1 HLA class II-binding peptides and compositions and methods comprising same (2014-07-01),

6. 7598221 - Synthetic HLA binding WT-1 peptide analogues and uses thereof (2009-10-06),

7. 7488718 - Synthetic HLA binding peptide analogues and uses thereof (2009-02-10),

Title: The Innovations of Javier Pinilla-Ibarz

Introduction

Javier Pinilla-Ibarz is a notable inventor based in New York, NY, who has made significant contributions to the field of cancer research. With a total of six patents to his name, he has focused on developing innovative methods for treating cancers that express the WT1 antigen. His work is pivotal in advancing therapeutic strategies for patients suffering from these types of cancers.

Latest Patents

Among his latest patents is the invention titled "WT1 HLA class II-binding peptides and compositions and methods comprising same." This invention provides WT1 peptides and outlines methods for treating, reducing the incidence of, and inducing immune responses against WT1-expressing cancers. The significance of this invention lies in its potential to improve treatment outcomes for patients with specific cancer types.

Career Highlights

Javier has worked with prestigious institutions such as the Sloan Kettering Institute for Cancer Research and Memorial Sloan Kettering Cancer Center. His experience in these leading research organizations has allowed him to collaborate with some of the brightest minds in the field of oncology.

Collaborations

Some of his notable coworkers include David A. Scheinberg and Rena May, who have also contributed to advancements in cancer research. Their collaborative efforts have further enhanced the impact of their work in the medical community.

Conclusion

Javier Pinilla-Ibarz's contributions to cancer research through his innovative patents and collaborations highlight his commitment to improving patient care. His work continues to inspire advancements in the treatment of WT1-expressing cancers.

Profile summary based on public USPTO records.